Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter ...

We couldn’t find any results matching your search. ... EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort May 23, 2025 — 09:57 am EDT.

Exelixis EXEL announced encouraging results from an expansion cohort of the early to mid-stage study of its next-generation oral TKI, zanzalintinib, in combination with either Bristol Myers' BMY ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter ...

Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on Exelixis (EXEL – Research Report). The associated price target remains the same with $32.00. Derek Archila has given his ...

Exelixis Inc. research and ratings by Barron's. View EXEL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.